Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

PARAMUS, N.J., June 26, 2026 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto, Japan; President, Toru Nakai) has entered into an...